Abstract 55P
Background
Epidermal Growth Factor Receptor (EGFR) represents one of the main molecular druggable targets in non-small-cell lung cancer (NSCLC). Osimertinib is an irreversible EGFR-tyrosine kinase inhibitor currently recognised as the standard of care for first-line treatment of EGFR-positive patients with common mutations (L858R or ex19del). Next Generation Sequencing (NGS) is recommended for routine use to detect gene mutation in NSCLC; moreover, NGS can quantitate the proportion of mutant variant reads for each mutation, the variant allele frequency (VAF). EGFR-VAF determined by liquid biopsy is known to be a prognostic factor in NSCLC patients. The role of EGFR-VAF determined on histological specimen in patients receiving first-line osimertinib is unclear.
Methods
From February 2019 to April 2023 a cohort of 68 patients with diagnosis of advanced EGFR mutated NSCLC started first-line osimertinib at San Raffaele Hospital, in Milan (Italy). We excluded from our analysis patients with VAF value unavailable (n=20). VAF was determined by NGS in pre-treatment baseline tissue samples.
Results
48 NSCLC patients were included in our analysis. Median EGFR-VAF was 31%, mean 35.9%, first quartile 17%, third quartile 52%. Cut-off of 50% was established to distinguish patients in high-VAF group (hVAF) and low-VAF (lVAF). Applying Log Rank test progression-free survival (PFS) was significantly shorter in hVAF patients [HR 0,30 (95% CI 0.12-0.8, p = 0.01)] than in lVAF group. With the limits of a 14.9 months median follow up, overall survival was significantly shorter in patients with high VAF [HR 0.19 (95% CI 0.056-0.648, p = 0.003)]. No correlation with other features (age, sex, smoke status, metastatic sites, PD-L1 expression) was found in covariate analysis, except for the mutation site L858R or ex19del, the latter being more frequently associated with hVAF.
Conclusions
High EGFR VAF on tissue seems to be predictive of a reduced response to osimertinib in NSCLC. Our findings must be validated on a greater number of cases, and a longer follow up is needed to confirm the correlation with shorter overall survival.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
S.T. Riva.
Funding
Has not received any funding.
Disclosure
R. Ferrara: Financial Interests, Personal, Advisory Board, In April 2022: MSD; Financial Interests, Personal, Advisory Board: Beigene; Financial Interests, Institutional, Invited Speaker: MSD, Pfizer, AstraZeneca, Roche, Sanofi, Novartis, BMS, Ipsen, Daiichi Sankyo Company. S. Pilotto: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, AstraZeneca, MSD, Roche, Amgen, Novartis, Takeda, Sanofi; Financial Interests, Personal, Advisory Board: MSD, Amgen, AstraZeneca, Novartis, Eli Lilly, Sanofi; Financial Interests, Personal, Research Grant: Bristol Myers Squibb, AstraZeneca; Non-Financial Interests, Personal, Principal Investigator: AstraZeneca, Roche, BMS. A. Bulotta: Financial Interests, Personal, Advisory Board: Roche, BMS, AstraZeneca; Financial Interests, Institutional, Invited Speaker: BMS, MSD, AstraZeneca, Eli Lilly. M. Reni: Financial Interests, Personal, Advisory Board: Celgene, Eli Lilly, Pfizer, Baxalta, Shire, Novocure, Novartis, Boston Biomedicals; Non-Financial Interests, Institutional, Principal Investigator: Celgene. M. Milella: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Pfizer, Merck-Serono, Novartis, Ipsen, Viatris; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Institutional, Funding: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study
Presenter: Christophe Mapendano
Session: Cocktail & Poster Display session
Resources:
Abstract